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The longitudinal evolution of HIV-1 phenotypes 
was studied in a cohort of six vertically infected 
children with early onset and rapid progression of 
clinical disease. Among 30 viral isolates obtained 
from peripheral blood, tropisms for both human 
blood-derived cells (macrophages, T-lympho- 
cytes), and for human neural (brain-derived) cells 
(microglia, astrocytes) were determined, as was 
chemokine co-receptor usage. All children har- 
bored from birth macrophage-tropic isolates 
using the CCR5 co-receptor. Two children later 
developed T-cell tropic isolates with CXCR4 
and CCR3 usage. While all six patients developed 
neurological abnormalities, only three produced 
neural cell tropic isolates, which used CCR5. How- 
ever, early and persistent finding of both astro- 
cyte- and microglia-tropic isolates in one patient 
did associate with the most rapid progression to 
brain atrophy among the six patients. Viral 
phenotypic properties determined in cell culture 
did not specifically predict clinical features or 
course, and the development of AIDS did not 
coincide with, or depend on, the appearance 
T-tropic, syncytia-inducing viruses. J. Med. 
Virol. 67: 1-8,2002. 
KEY WORDS: HIV-1 infections; pediatrics; 
neuroglia; astrocytes; macro- 
phages; chemokine receptors 
INTRODUCTION 
Children with human immunodeficiency virus type 1 
(HIV-1) infection may develop a broad spectrum of 
clinical disease that is variable in both age at onset 
of serious disease and progression [Blanche et al., 
1990, 1994; Newell, 19911. Most pediatric infection is 
acquired perinatally and, in infants, HIV-1 disease 
progression may be influenced by the timing of virus 
transmission to the infant, i.e., in utero or intrapartum. 
Rapid disease progression is reported in 10-20% of 
infected infants, and is more probable with in utero 
transmission [Dickover et al., 1994; Mayaux et al., 
1996; Kuhn et al., 19971. These infants are more likely 
to have an accelerated decline in their CD4+ lympho- 
cyte counts, experience early developmental delay, 
develop AIDS defining conditions, and die before 4 years 
of age [Scott et al., 1989; Blanche et al., 1990; Newell, 
1991; Duliege et al., 1992; Tovo et al., 1992; Turner 
et al., 19931. Other children have a later onset and 
slower progression of disease, with a slower decline in 
immune function andlonger survival [Auger et al., 1988; 
Scott et al., 1989; Blanche et al., 1990; European 
Collaborative Study, 1991; Duliege et al., 1992; Blanche 
et al., 1994; Italian Registrar, 19941. In the current era 
of highly active antiretroviral therapy and early HIV-1 
diagnosis, it is anticipated that fewer infants will 
develop encephalopathy and rapid disease progression. 
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Vertical transmission of HIV-1 may be associated 
with a phenotypically homogeneous population of 
viruses at birth [McNearney et al., 1992; Wolinsky 
et al., 1992; Mulder-Kampinga et al., 19931. Then 
longitudinal changes may occur in HIV-1 viral geno- 
type, i.e., the genetic sequence in certain viral genes, or 
in HIV-1 viral phenotype, i.e., the cellular tropisms and 
co-receptor usage. However, longitudinal changes in 
viral genotype or phenotype have not been definitively 
correlated with clinical disease progression in indivi- 
dual patients [Fitzgibbon et al., 19981. The immune 
response and possibly other selective pressures may act 
on the viral envelope glycoprotein gene region during 
infection to drive the evolution of the virus population 
toward expanding cell tropisms and increased cyto- 
pathicity. Several studies, including our own, have 
shown that viral sequences in the envelope glycoprotein 
are more homogeneous early in infection, and sequence 
diversity increases with disease progression and a fall 
in CD4+ T-cell count [Hutto et al., 1996; Nowak and 
Bangham, 1996; Salvatori et al., 1997; Markham et al., 
19981. Most viruses isolated from adults and children 
close to the time of transmission are macrophage tropic 
and non-syncytium-inducing (NSI) [Roos et al., 1992; 
Spencer et al., 1994; Balotta et al., 19971, and they use 
predominantly chemokine receptor CCR5 as co-recep- 
tor [Zhang et al., 19981. In older children and adults, 
the emergence of T-cell tropic, syncytium-inducing (SI) 
virus isolates using chemokine receptor CXCR4 and, in 
some cases, CCR3, is associated with rapid disease 
progression [Cheng-Mayer et al., 1989; Tersmette et al., 
1989; De Rossi et al., 1993; Balotta et al., 1996; Coombs 
et al., 1996; Katzenstein et al., 1996; Koot et al., 1996; 
Fitzgibbon et al., 1998; Zhang et al., 19981. During the 
first year of life, however, NSI isolates seem to pre- 
dominate irrespective of clinical course [Spencer et al., 
1994; van't Wout et al., 19941. After progression of 
disease occurred, the majority of viral isolates acquired 
the ability to use CXCR4 and, in some cases, CCR3, 
while losing the ability to use CCR5. 
While neurological illness is prominent in rapidly 
progressive pediatric HIV-1 infection, there are limited 
prospective data on viral tropisms for brain-derived cell 
types. Productive HIV-1 infection in the brain occurs in 
microglia, which are resident central nervous system 
(CNS) cells of monocyte origin [Bagasara et al., 19961. 
In adults, HIV-1 isolates exhibit tropism for microglia 
that usually correlates with tropism for macrophages 
[Strizki et al., 19961 and the use of the CCR5 and CCR3 
co-receptors [He et al., 19971. In contrast, HIV-infection 
of astrocytes is restrictive or nonproductive, with very 
limited virus production and the predominant expres- 
sion of nonstructural HIV proteins such as nef [Torna- 
tore et al., 1991, 1994a,b; Blumberg et al., 1994; Ranki 
et al., 19951. Cellular tropism for astrocytes loosely 
correlates with tropism for lymphocytes [McCarthy 
et al., 19981, and neurological disease during HIV-1 
infection may result from neuronal and astrocyte 
apoptosis mediated by HIV-1 strains that interact with 
CXCR4 receptors on these neuroepithelial lineage cells 
[Ohagen et al., 19991. Restricted or nonproductive 
HIV-1 infection of astrocytes occurs in both pediatric 
and adult brains, suggesting that astrocytes function as 
a reservoir for latent virus in the CNS [Saito et al., 
1994; Tornatore et al., 1994a; Ranki et al., 1995; 
Takahashi et al., 19961. 
This study assesses the longitudinal evolution of 
cellular tropisms manifested by HIV-1 viruses isolated 
prospectively from a cohort of vertically infected chil- 
dren with early onset and rapid progression of clinical 
disease. The study specifically examines (1) tropisms 
for both human blood-derived cells (macrophages, T 
lymphocytes), and for human neural (brain-derived) 
cells (microglia, astrocytes); and (2) the corresponding 
longitudinal evolution of co-receptor usage by the viral 
isolates. These prospective data provide insight into the 
changes in viral phenotypic characteristics evolving 
early in the lifetimes of children with rapid HIV-1 
disease progression. 
MATERIALS AND METHODS 
Description of the Cohort 
A total of 35 children with perinatally acquired HIV 
infection were followed prospectively from birth. For all 
study patients, written informed consent was obtained 
from the child's parent or legal guardian. This study 
was approved by, and conducted according to the 
guidelines of the institutional review board of the 
University of Miami School of Medicine, the Medical 
Sciences Subcommittee for the Protection of Human 
Subjects. Clinical and laboratory data were collected 
every 3 months, and blood samples were drawn for HIV 
culture and plasma storage starting in the perinatal 
period and continuing throughout life. Six children 
with rapid disease progression were selected for 
this study based on having an adequate number of 
isolates to study. Rapid progressors had absolute CD4+ 
counts of 1 1,000/mm3 during the first year of life, or 
< 500/mm3 during the second year of life, or had one or 
more of the AIDS defining criteria [Centers for Disease 
Control, 19941 during the first 2 years of life. 
Viral Assays 
HIV-1 viral load was determined in plasma using the 
standard Roche Amplicor HIV-1 Monitor Test (Roche 
Diagnostics Corporation, Indianapolis, IN). HIV-1 iso- 
lates were obtained by culture of the individual's 
peripheral blood mononuclear cells (PBMC) according 
to standard HIV-1 isolation techniques [AIDS Clinical 
Trials Group, 19941. Virus production was monitored 
by measuring HIV-1 p24 antigen levels, using a com- 
mercial enzyme-linked immunoassay kit (Beckman 
Coulter, Hialeah, FL). 
Virus Titration and TCID50 Calculation 
Virus stocks were prepared when p24 antigen 
exceeded 10 ng/ml, and the titers were determined by 
limiting dilution to obtain the 50% tissue culture 
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infectious dose (TCID50) as  described in the AIDS 
Clinical Trials Group (ACTG) virology manual for HIV 
laboratories, though with some modifications [AIDS 
Clinical Trials Group, 19941. Briefly, serial fourfold 
dilutions of virus stocks, from 1:12 to 49,152, in a final 
volume of 150 111, were incubated in triplicates in flat- 
bottomed 96-well tissue culture plates with 50 p1 of 
phytohemagglutinin assay (PHA)-stimulated PBMC 
containing 200,000 cells, pooled from two uninfected 
donors. At day 4, 125 p1 of the culture media were 
removed and replaced with 150 p1 of fresh media. 
Supernatants were tested for the presence of p24 
antigen at  day 7. The TCIDBO were calculated according 
to the Spearman-Karber method as described in the 
ACTG manual [AIDS Clinical Trials Group, 19941. 
Cell Culture 
Fetal CNS tissue for the preparation of astrocyte 
cultures was obtained from the Human Embryology 
Laboratory, University of Washington (Seattle, WA). 
Procedures for the procurement and use of human fetal 
CNS tissue were approved and monitored by the 
Medical Sciences Subcommittee for the Protection of 
Human Subjects of the University of Miami School of 
Medicine. Primary fetal human astrocyte monolayers 
were grown to 80% confluency on poly-L-lysine-coated 
6-well multicluster tissue culture dishes in B16 
medium with 5 ng/ml basic fibroblast growth factor 
(bFGF) [McCarthy et al., 19951. Primary human 
microglia were isolated from adult spinal cord and 
plated on uncoated 6-well tissue culture dishes in RPMI 
medium containing 5% fetal bovine serum (FBS) 
[Whittemore et al., 19931. The T-cell lines, MT-2, 
C8166, and CEM x 174-GFP were cultured in RPMI 
medium- 10% FBS. Cell line HOS-CD4-CCR3 is from 
the NIH AIDS Research Reference and Reagent 
Program; it is propagated in DMEM medium contain- 
ing 10% FBS, and 0.5-1.0 yglml puromycin. Ghost- 
CCR5 cells were propagated in DMEM with 10 pg/ml of 
hygromycin, 500 yglml of G418, and 1 pg/ml of 
puromycin. CEM x 174-GFP and Ghost-CD4-CCR5 
cells were supplied by Dr. Weidong Xu (Dana Farber 
Cancer Center, Boston, MA). Primary human mono- 
cytes were obtained from gradient-purified PBMC by 
the plastic adherent technique [Cheng-Mayer et al., 
19891. Adherent cells were cultured for 7-10 days in 
RPMI medium containing 10% FBS and 10 ng of 
granulocyte-macrophage colony-stimulating factor 
(GIBCO-BRL, Gaithersburg, MD) per ml to allow dif- 
ferentiation into macrophages. 
Determination of Cellular Tropism 
Each isolate was tested for its ability to infect 
primary human astrocytes (astrocyte tropism), primary 
human microglia (microglia tropism), the immortalized 
T-cell line MT-2 (T-cell tropism), and primary human 
macrophages (macrophage tropism). Virus isolates that 
were "T-tropic" were further monitored for syncytia 
induction (SI) in cell culture. Cells were first treated 
with 2 pglml Polybrene (Sigma Chemical Co., St. Louis, 
MO) for 1 hr at  37'C and then incubated with the virus 
isolate at  a multiplicity of infection (moil of 500 TCID501 
lo5 cells for 2 hr  at  37'C. After this adsorption step, the 
cells were then washed and cultured in the appropriate 
medium. Supernatants were harvested at  0,3,7,  and 14 
days postinfection from all infections except for astro- 
cytes, in which case supernatants were harvested at  0, 
1, 2, 3, 4, and 7 days postinfection. Virus production 
was monitored by measuring the p24 antigen levels in 
the culture supernatants. Cultures were considered 
positive for viral growth if > 100 pglml of p24 was 
detected. A "weak positive" score was given if only 50- 
100 pg/ml of p24 was present, and a negative score if 
< 50 pglml was detected. 
Evaluation of Co-receptor Usage 
Determination of co-receptor usage was carried out 
using different cell lines expressing different co- 
receptors, CXCR4 (CEM x 174-GFP cells), CCR5 
(Ghost-CCR5 cells) and CCR3 (HOS-CD4-CCR3 
cells) [Cecilia et al., 1998; Morner et al., 19991. To test 
for co-receptor usage, all three cell lines were seeded at  
a density of 1 x lo6 cellslml into each well of a 24-well 
plate, infected with 5 ng p24 of HIV-1 per ml of cells, 
and on day 2-3 postinfection, the infected CEM x 174- 
GFP and Ghost-CCR5 cells were observed under the 
microscope for marker green fluorescent protein (GFP) 
expression. A well containing three times or more green 
fluorescent cells than the negative control was con- 
sidered positive. Negative control cells without HIV-1 
infection generally produced only one to two GFP 
expressing cells per well. HIV-1 strains SF2 or NL4-3 
was used as positive control for viruses that use CXCR4 
as co-receptor, and HIV-1 strain SF128A was used as 
control for viruses that use CCR5 as co-receptor. 
Infection by the positive control virus usually gave at  
least 7 times more GFP-expressing cells than back- 
ground control. For infection of HOS-CD4-CCR3, p24 
virus production was monitored by measuring HIV-1 
p24 antigen levels in the culture supernatants at  3 days 
postinfection. Cultures were considered positive for 
viral growth if > 100 pglml of p24 was detected. 
RESULTS 
Thirty peripheral blood isolates of HIV-1 were stu- 
died. These were obtained from six vertically infected 
pediatric patients, all of whom progressed rapidly to 
HIV-1 disease. All children were born between June 
1990 and July 1995. There were two females and four 
males in the cohort; all were of black African American 
or Caribbean descent. Three of these patients (patients 
422, 275, and 601) were presumed to be infected in 
utero, as  virus was detected by culture or viral RNA 
assay in blood samples obtained within 2 days of birth. 
The remaining three patients (patients 202, 290, and 
217) were apparently infected intrapartum. The 
patients were assessed for longitudinal progression of 
clinical disease, occurrence of neurological abnormal- 
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TABLE I. Longitudinal Summary of Patient Disease Progression, Neurological Abnormalities, and Cellular Tropism 
of Isolates 
CDC Neurological 
Patient Age m$" M T - ~ ~  astC Co-receptor usage classe abnormalitiesf 

















275 2 wk 
2 mo 
12 mo 






















"Primary macrophage tropism. 
b~-ce l l  tropism as defined by growth on the T-cell line MT-2, virus that grew in MT-2 cells were also SI 
'Primary istrocyte tropism: - 
- 
d ~ r i m a r y  microglia tropism. 
"CDC Clinical Category N, no signstsymptoms; A, mild signs/symptoms; B, moderate signs/symptoms; C, severe signs/symptoms. 
f~eurological abnormalities: -, no abnormalities found; +, developmental delay and/or cognitive abnormalities; ++, CNS atrophy andtor brain 
calcification; ND, not determined. 
ities, CD4+ lymphocyte count, viral load, and the 
cellular tropisms of their viral isolates. Table I and 
Figure 1 (arranged arbitrarily by patient number) 
summarize the data from all HIV-1 isolates. All 
children developed a CDC Category C AIDS defining 
illness [Centers for Disease Control, 19941 during the 
first 2 years of life. Five of the children died by 30 
months of age, and one child (patient 217) still survives. 
Neurological abnormalities ranging from developmen- 
tal delay and/or cognitive dysfunction to CNS atrophy 
and/or brain calcification were found as early as 2 
months of age in one child, and in all children by 20 
months of age. Therefore, these patients represent a 
cohort of vertically HIV-1 infected pediatric patients 
whose clinical disease progressed rapidly and included 
neurological abnormalities within the first two years of 
life. Of the five patients that died, four had declining 
CD4 counts during the course of their illness (Fig. 1). 
The surviving child (patient 217) is severely immuno- 
suppressed, as evidenced by very low CD4 values. 
HIV-1 viral load (viral RNA copies/ml) values are avail- 
able for five of the six children and show progressive 
increase in viral load in three. Four of the children 
(patients 422, 601, 202, and 217) received zidovudine 
monotherapy within the first 4 months of life because of 
early diagnosis of HIV-1 infection and evidence of 
clinical disease. 
The longitudinal collection of HIV-1 isolates from 
each patient was assessed for cellular tropism, which 
was defined by the ability of a given isolate to grow in 
primary human macrophages, an immortalized human 
T-lymphocyte cell line (MT-2), primary human astro- 
cytes, and primary human microglia. Between birth 
and 12 months of age, all six of the children harbored 
viruses that were macrophage tropic. In the two chil- 
dren who later developed T-tropic viral isolates 
(patients 202 and 217), progression to severe disease 
or development of neurological abnormalities did not 
predict or depend upon the appearance of the T-tropic 
phenotype. Within the first year of life, patient 202 
displayed weak gross motor skills and only later, a t  20 
months of age, produced viral isolates that had gained 
T-cell tropism in addition to macrophage tropism 
(Table I, Fig. 1A). This expanded cellular tropism 
coincided with the progression to Category C illness 
as well as  developmental delay. By 38 months of age, 
this patient had delayed fine motor skills and both 
expressive and receptive language deficits. In contrast 
to patient 202, patient 217 did not develop dual tropic 
viruses (able to infect both macrophages and MT-2 
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Fig. 1. Individual longitudinal profiles of clinical disease stage, 
cellular tropisms, CD4+ lymphocyte counts (cells/mm3), and human 
immunodeficiency virus type 1 (HIV-1) viral load (RNA copieslml) in 
six vertically infected children with rapid clinical disease progression. 
Clinical disease stage according to Centers of Disease Control (CDC) 
classification is indicated along the x-axis: open bar, CDC class N; 
horizontally striped bar, CDC class A; horizontally cross-hatched bar, 
cells) until 38 months of age, about 32 months after 
progression to severe disease, and 26 months after the 
appearance of neurological abnormalities (Table I, 
Fig. IF). The remaining four children harbored macro- 
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phage tropic viruses throughout life, even after pro- 
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death. The appearance of viral isolates with specific cellular tropisms 
are indicated along the x-axis of each profile: mQ, macrophage (NSI); 
ast, astrocyte; pgl, microglia; MT-2, T-tropic (SI) virus determined by 
growth in MT-2 cells as described in the Materials and Methods 
section. 
gression to severe disease and the development of 
neurological abnormalities. 
Only two of the six children, patients 202 and 422, 
ever exhibited viral isolates with cellular tropisms for 
both astrocytes and microglia (Table I). In these two 
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children, astrocyte tropism persisted, whereas micro- 
glia tropism was transient. A third child, patient 217, 
produced astrocyte-tropic isolates within the first 2 
weeks of life, but this astrocyte tropism was subse- 
quently lost from later isolates. All microglia-tropic 
isolates were found to be macrophage-tropic. There was 
no correlation between a change in neural cell tropism 
and a change in neurological status. Patient 422 did not 
harbor T-tropic isolates at any time and consistently 
produced macrophage-tropic strains. Therefore, we did 
not observe a correlation between emergence of T-cell 
tropism and neural cell tropism (astrocytes or micro- 
glia) in this cohort. 
Additional experiments were performed to define the 
co-receptor usage of the isolates. All isolates produced 
by the cohort during the first year of life used the CCR5 
co-receptor, which correlated with macrophage tropism 
and the NSI phenotype (Table I). When patients 202 
and 217 developed T-tropic isolates in addition to their 
macrophage-tropic isolates later in the course of 
disease, co-receptor usage of their respective isolate 
populations expanded to include CXCR4 and CCR3, as 
well as CCR5. Interestingly, all viruses that have 
evolved to use the CXCR4 co-receptor have also evolved 
to use CCR3, and there appeared to be a correlation 
between CCR3 and CXCR4 co-receptor usage, at least 
in the children that we have tested. In contrast, 
patients 202, 422, and 217 produced isolates during 
the first year of life that were microglia- andlor astro- 
cyte-tropic but used only the CCR5 co-receptor. Patient 
202 at 2 months, and patient 422 at birth, 2 months, 
and 6 months, had isolate populations with both 
astrocyte and microglia tropisms. Thus, diverse neural 
cell tropisms were seen in viral isolate populations 
using only CCR5. 
DISCUSSION 
In this study of six vertically HIV-1-infected pediatric 
patients with rapid disease progression, viral pheno- 
type properties did not specifically predict clinical 
features or course. Macrophage-tropic viral isolates 
and CCR5 chemokine co-receptor usage predominated 
and T-tropic (SI) isolates, when they occurred, arose 
later in the clinical course. There was no correlation 
between the timing of HIV-1 infection, i.e., in utero 
versus peripartum, and rapid clinical progression, 
although, consistent with the Women and Infants 
Transmission Study [Shearer et al., 19971, all patients 
had high viral load (> 500,000 RNA copies/ml) during 
the first 2 months of life. Clinical neurological mani- 
festations of HIV-1, i.e., encephalopathy and develop- 
mental delay, did not depend on the emergence of virus 
strains in the peripheral circulation that were infec- 
tious for microglia and/or astrocytes in vitro. Macro- 
phage tropism was not equivalent to, nor did it predict, 
microglia tropism, although in this cohort, all microglia- 
tropic isolates were also macrophage-tropic. Astrocyte- 
tropic isolates obtained from three of the six patients 
(patients 202, 422, and 217) were also macrophage- 
tropic, and the astrocyte-tropic isolates detected earlier 
in the disease course used the CCR5 co-receptor only 
(Table I). Furthermore, rapid disease progression and 
death occurred in most cases without the emergence of 
T-tropic (SI) strains at all, and the development of 
AIDS did not coincide with or depend on the appear- 
ance of quasi-species able to infect T-cell lines. When SI 
strains arose (patients 202 and 217), there was a 
simultaneous emergence of viruses that acquired dual 
CXCR4 and CCR3 usage in addition to CCR5. It is not 
clear whether this is due to a mixture of strains of 
viruses that each use a different co-receptor, or to a 
single virus that can use CXCR4 and CCR3 in addition 
to CCR5. Further cloning of the viruses will be needed 
to resolve this issue. 
These data are consistent with two prior longitudinal 
studies in vertically HIV-1-infected children [Hutto 
et al., 1996; Fitzgibbon et al., 19981, and they suggest 
that progression of HIV-1 illness in very young children 
frequently does not associate with SI virus phenotype. 
In a study of 48 children, Fitzgibbon et al. [I9981 
observed that rapid progressors in that cohort were no 
more likely to produce SI than NSI viruses, and some 
rapid progressors died without manifesting SI strains. 
Hutto et al. [I9961 studied viral genetic diversity and 
cellular tropisms in perinatally infected twins with 
discordant disease courses, and found that the rapid 
progressor twin did not produce SI or T-tropic isolates 
from peripheral blood. 
A potential pitfall in the interpretation of our as well 
as similar studies is the use of viral isolates derived 
longitudinally from peripheral blood. These blood isola- 
tes are a mixed population of quasi-species, and could 
be expected to exhibit multiple viral phenotypes during 
the longitudinal course of HIV-1 infection in the 
individual patient. Given the neuroanatomical seques- 
tration of the CNS, these peripheral blood-derived 
isolates may not reflect the population of HIV-1 quasi- 
species resident within the CNS at the time of isolation. 
Sequestration of the virus in the CNS-resident micro- 
glia cells enables local evolution of CNS-specific quasi- 
species, which may be independent and divergent 
from peripheral quasi-species [Gonzalez-Scarano and 
Baltuch, 19991. However, perivascular microglia at 
the blood-brain barrier may be exposed to peripheral 
HIV-1 quasi-species by circulating lymphoid cells 
[Gonzalez-Scarano and Baltuch, 19991. Thus, although 
the peripheral HIV-1 isolates may not reflect the CNS 
quasi-species at the time of isolation, these peripheral 
isolates could reflect the circulating subpopulations of 
HIV-1 that are capable of infecting the blood-brain 
barrier and entering the CNS as early as birth and 
throughout the course of disease. Therefore, periph- 
erally derived isolates are potentially relevant to the 
emergence and progression of clinical neurological 
disease. In our cohort of six children, the one child 
with isolate populations that were both astrocyte-tropic 
and microglia-tropic at birth (patient 422) did have the 
most rapid onset of more severe neurological abnorm- 
alities (CNS atrophy by 6 months of age). 
Viral Phenotypes in HIV-Infected Children 
In this cohort of six pediatric patients with rapid 
progression of HIV-1-related disease, there was no 
definitive association between clinical neurological 
complications and viral phenotype (cell tropism) or co- 
receptor usage. All six patients in the cohort developed 
neurological abnormalities, but neural cell tropic 
viruses were only detected in three patients at any 
point in life. However, the early and persistent finding 
of both astrocyte and microglia tropic isolates in one 
patient (patient 422) did associate with the most rapid 
progression to CNS atrophy among the six patients. 
Early (patient 217) or early and persistent (patient 202) 
astrocyte tropism without microglia tropism did not 
associate with more rapid presentation of neurological 
complications. In that peripheral blood-derived isolates 
may reflect the population of viruses capable of crossing 
the blood brain barrier and promoting CNS infection, 
the isolates produced by patient 422 during the first 
several months of life may have been optimal for 
seeding, establishing, and amplifying productive infec- 
tion of the CNS. Microglia-tropic viruses would be 
capable of establishing productive CNS infection in 
microglia, while astrocyte-tropic viruses would also 
establish restricted or latent CNS infection in astro- 
cytes. The combination of these cellular tropisms could 
ultimately amplify the viral burden in the CNS and 
accelerate the neurological manifestations of HIV-1 
infection in the pediatric patient. 
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